Frequency of MELAS main mutation in a phenotype-targeted young ischemic stroke patient population

Turgut Tatlisumak1,2,3, Jukka Putaala4, Markus Innilä5

  • 1Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Per Dubbsgatan 14, POB 430, 40530, Gothenburg, Sweden. turgut.tatlisumak@neuro.gu.se.

Journal of Neurology
|November 15, 2015
PubMed

Insights

Genetic testing identified previously unrecognized carriers of the main mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) mutation in young ischemic stroke patients. This highlights the importance of considering MELAS in stroke evaluations.

Area of Science:

  • Neurology
  • Genetics
  • Mitochondrial Biology

Background:

  • Mitochondrial diseases, particularly MELAS, can be associated with ischemic stroke in younger individuals.
  • Identifying these underlying conditions is crucial for accurate diagnosis and management.

Purpose of the Study:

  • To investigate the prevalence of undiagnosed MELAS in a cohort of young ischemic stroke patients.
  • To identify carriers of the common m.3243A>G MELAS mutation within this population.

Main Methods:

  • Phenotypic screening of 3291 young ischemic stroke patients for MELAS suggestive features.
  • Genetic analysis of blood samples for the m.3243A>G mutation in identified patients.
  • Review of clinical and MRI data of mutation carriers.

Main Results:

  • Four previously unrecognized carriers of the MELAS m.3243A>G mutation were identified among 238 analyzed patients.
  • Most carriers presented with typical ischemic stroke features, with some exhibiting hearing loss or specific MRI findings.

Conclusions:

  • Genetic testing based on suggestive phenotypes can uncover MELAS mutation carriers among young ischemic stroke patients.
  • While identifying carriers is important, it does not definitively prove MELAS as the cause of stroke without further clinical correlation.

Related Concept Videos

Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.0K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
109
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Point and Frameshift Mutations01:30

Point and Frameshift Mutations

Point mutations are genetic alterations involving the change of a single nucleotide base pair in DNA. Depending on how the alteration affects protein synthesis, they can lead to various consequences.Point mutations fall into the following types:Silent mutations occur when a nucleotide change does not alter the amino acid sequence due to the redundancy of the genetic code. For instance, changing ACC to ACA still encodes threonine, leaving the protein function unaffected. This occurs because...
1.6K